Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Drug Free Solution's EV-to-EBIT or its related term are showing as below:
DSOL's EV-to-EBIT is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 15.775 * Ranked among companies with meaningful EV-to-EBIT only.
Drug Free Solution (OTCPK:DSOL) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Drug Free Solution's Enterprise Value for the quarter that ended in Feb. 2014 was $9.70 Mil.
Drug Free Solution's EBIT for the trailing twelve months (TTM) ended in Feb. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Drug Free Solution EV-to-EBIT Related Terms
Drug Free Solution EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Drug Free Solution's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Drug Free Solution's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Drug Free Solution EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Drug Free Solution's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Drug Free Solution's EV-to-EBIT falls into.
Drug Free Solution's current Enterprise Value is $0.11 Mil.
Drug Free Solution's EBIT for the trailing twelve months (TTM) ended in Feb. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Drug Free Solution (DSOL) has a EV-to-EBIT of -0.13 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Drug Free Solution and its competitors.
Is Drug Free Solution's EV-to-EBIT too high?
Drug Free Solution's current EV-to-EBIT is -0.13.
How does Drug Free Solution's EV-to-EBIT compare to USEL and ZZLL?
Drug Free Solution's EV-to-EBIT of -0.13 can be compared against companies in the Healthcare Providers & Services industry. The industry median EV-to-EBIT is 15.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.78, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Drug Free Solution and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Drug Free Solution's current EV-to-EBIT is -0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drug Free Solution stock overvalued right now?
Drug Free Solution (DSOL) has a current EV-to-EBIT of -0.13. The current EV-to-EBIT is -0.13. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Drug Free Solution (DSOL), the current EV-to-EBIT is -0.13 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Drug Free Solution Inc is a United States based holding company that owns and operates various subsidiaries in the healthcare industry. It is focused on acquiring healthcare operations that focus on Home Healthcare, Developmental Disabilities, Hospice Care, Skilled Nursing, Residential Rehabilitation, Home & Community Based Services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSOL has been successfully added to your 
